within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02A_HormonesAndRelatedAgents.L02AE01_Buserelin;

model Buserelin
  extends Pharmacolibrary.Drugs.ATC.L.L02AE01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L02AE01</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Buserelin is a synthetic analogue of the gonadotropin-releasing hormone (GnRH) used primarily in the treatment of hormone-sensitive cancers such as prostate cancer, endometriosis, and occasionally in assisted reproduction. It acts as a GnRH agonist, causing downregulation of pituitary secretion of gonadotropins and subsequent reduction in sex steroid production. The drug is approved and in current clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy male volunteers after single subcutaneous administration.</p><h4>References</h4><ol><li><p>Blom, JH, et al., &amp; Krauss, B (1989). Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients. <i>Urological research</i> 17(1) 43–46. DOI:<a href=\"https://doi.org/10.1007/BF00261050\">10.1007/BF00261050</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2493705/\">https://pubmed.ncbi.nlm.nih.gov/2493705</a></p></li><li><p>Fraser, HM (1993). GnRH analogues for contraception. <i>British medical bulletin</i> 49(1) 62–72. DOI:<a href=\"https://doi.org/10.1093/oxfordjournals.bmb.a072606\">10.1093/oxfordjournals.bmb.a072606</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8324616/\">https://pubmed.ncbi.nlm.nih.gov/8324616</a></p></li><li><p>Holland, FJ, et al., &amp; Leeder, S (1986). Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. <i>The Journal of clinical endocrinology and metabolism</i> 63(5) 1065–1070. DOI:<a href=\"https://doi.org/10.1210/jcem-63-5-1065\">10.1210/jcem-63-5-1065</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3093518/\">https://pubmed.ncbi.nlm.nih.gov/3093518</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Buserelin;
